St. Jude Medical


has appointed a new chief medical officer to direct clinical affairs in the company's cardiac rhythm management division.

Mark D. Carlson will take the helm of the group on Nov. 13. Carlson recently chaired the Heart Rhythm Society's task force to recommend study policies on the performance of medical devices after they've entered the market, following last year's broad recalls of heart devices made by Guidant.

At St. Jude, Carlson will coordinate clinical studies on new and existing heart devices and therapies and will serve as a liaison to the medical community, the company says.

"As a physician who has worked closely with patients and industry stakeholders in helping to promote superior care, research, education and sound public policy, Dr. Carlson will provide St. Jude Medical with important insights and perspective," said Michael Coyle, president of St. Jude's cardiac rhythm management business.

Boston Scientific

(BSX) - Get Report

acquired Guidant earlier this year following a bidding war with health care giant

Johnson & Johnson

(JNJ) - Get Report

. After the product recalls, sales of heart devices took a hit across the board.

St. Jude's shares dipped 17 cents to $37 Monday.